vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.
UNIVERSAL TECHNICAL INSTITUTE INC is the larger business by last-quarter revenue ($220.8M vs $180.9M, roughly 1.2× AVANOS MEDICAL, INC.). UNIVERSAL TECHNICAL INSTITUTE INC runs the higher net margin — 5.8% vs -0.7%, a 6.5% gap on every dollar of revenue. On growth, UNIVERSAL TECHNICAL INSTITUTE INC posted the faster year-over-year revenue change (9.6% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-19.2M). Over the past eight quarters, UNIVERSAL TECHNICAL INSTITUTE INC's revenue compounded faster (9.5% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.
AVNS vs UTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $220.8M |
| Net Profit | $-1.3M | $12.8M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 7.1% |
| Net Margin | -0.7% | 5.8% |
| Revenue YoY | 0.7% | 9.6% |
| Net Profit YoY | 99.7% | -42.1% |
| EPS (diluted) | $-0.02 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $220.8M | ||
| Q3 25 | $177.8M | $222.4M | ||
| Q2 25 | $175.0M | $204.3M | ||
| Q1 25 | $167.5M | $207.4M | ||
| Q4 24 | $179.6M | $201.4M | ||
| Q3 24 | $170.4M | $196.4M | ||
| Q2 24 | $171.7M | $177.5M | ||
| Q1 24 | $166.1M | $184.2M |
| Q4 25 | $-1.3M | $12.8M | ||
| Q3 25 | $-1.4M | $18.8M | ||
| Q2 25 | $-76.8M | $10.7M | ||
| Q1 25 | $6.6M | $11.4M | ||
| Q4 24 | $-397.3M | $22.2M | ||
| Q3 24 | $4.3M | $18.8M | ||
| Q2 24 | $1.8M | $5.0M | ||
| Q1 24 | $-900.0K | $7.8M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 7.1% | ||
| Q3 25 | 0.1% | 11.2% | ||
| Q2 25 | -42.6% | 6.9% | ||
| Q1 25 | 6.1% | 8.1% | ||
| Q4 24 | -233.0% | 13.6% | ||
| Q3 24 | 7.0% | 13.3% | ||
| Q2 24 | 3.7% | 4.2% | ||
| Q1 24 | 2.4% | 6.1% |
| Q4 25 | -0.7% | 5.8% | ||
| Q3 25 | -0.8% | 8.4% | ||
| Q2 25 | -43.9% | 5.2% | ||
| Q1 25 | 3.9% | 5.5% | ||
| Q4 24 | -221.2% | 11.0% | ||
| Q3 24 | 2.5% | 9.6% | ||
| Q2 24 | 1.0% | 2.8% | ||
| Q1 24 | -0.5% | 4.2% |
| Q4 25 | $-0.02 | $0.23 | ||
| Q3 25 | $-0.03 | $0.33 | ||
| Q2 25 | $-1.66 | $0.19 | ||
| Q1 25 | $0.14 | $0.21 | ||
| Q4 24 | $-8.64 | $0.40 | ||
| Q3 24 | $0.09 | $0.35 | ||
| Q2 24 | $0.04 | $0.09 | ||
| Q1 24 | $-0.02 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $162.8M |
| Total DebtLower is stronger | $90.3M | $101.4M |
| Stockholders' EquityBook value | $778.2M | $335.9M |
| Total Assets | $1.1B | $834.0M |
| Debt / EquityLower = less leverage | 0.12× | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $162.8M | ||
| Q3 25 | $70.5M | $169.1M | ||
| Q2 25 | $90.3M | $70.7M | ||
| Q1 25 | $97.0M | $96.0M | ||
| Q4 24 | $107.7M | $172.0M | ||
| Q3 24 | $89.0M | $161.9M | ||
| Q2 24 | $92.2M | $115.5M | ||
| Q1 24 | $75.8M | $116.1M |
| Q4 25 | $90.3M | $101.4M | ||
| Q3 25 | $93.4M | $87.1M | ||
| Q2 25 | $95.7M | $73.8M | ||
| Q1 25 | $98.0M | $94.4M | ||
| Q4 24 | $125.3M | $120.1M | ||
| Q3 24 | $152.6M | $125.7M | ||
| Q2 24 | $164.9M | $137.3M | ||
| Q1 24 | $167.2M | $141.9M |
| Q4 25 | $778.2M | $335.9M | ||
| Q3 25 | $778.0M | $328.1M | ||
| Q2 25 | $776.3M | $306.8M | ||
| Q1 25 | $839.4M | $293.9M | ||
| Q4 24 | $828.5M | $280.0M | ||
| Q3 24 | $1.2B | $260.2M | ||
| Q2 24 | $1.2B | $239.4M | ||
| Q1 24 | $1.2B | $232.6M |
| Q4 25 | $1.1B | $834.0M | ||
| Q3 25 | $1.1B | $826.1M | ||
| Q2 25 | $1.0B | $740.8M | ||
| Q1 25 | $1.1B | $720.4M | ||
| Q4 24 | $1.2B | $753.8M | ||
| Q3 24 | $1.7B | $744.6M | ||
| Q2 24 | $1.7B | $706.0M | ||
| Q1 24 | $1.7B | $702.1M |
| Q4 25 | 0.12× | 0.30× | ||
| Q3 25 | 0.12× | 0.27× | ||
| Q2 25 | 0.12× | 0.24× | ||
| Q1 25 | 0.12× | 0.32× | ||
| Q4 24 | 0.15× | 0.43× | ||
| Q3 24 | 0.12× | 0.48× | ||
| Q2 24 | 0.13× | 0.57× | ||
| Q1 24 | 0.14× | 0.61× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $3.1M |
| Free Cash FlowOCF − Capex | $21.3M | $-19.2M |
| FCF MarginFCF / Revenue | 11.8% | -8.7% |
| Capex IntensityCapex / Revenue | 3.8% | 10.1% |
| Cash ConversionOCF / Net Profit | — | 0.24× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $16.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $3.1M | ||
| Q3 25 | $14.0M | $57.1M | ||
| Q2 25 | $6.8M | $18.1M | ||
| Q1 25 | $25.7M | $-789.0K | ||
| Q4 24 | $57.9M | $23.0M | ||
| Q3 24 | $23.0M | $67.5M | ||
| Q2 24 | $27.8M | $10.0M | ||
| Q1 24 | $-8.0M | $-2.5M |
| Q4 25 | $21.3M | $-19.2M | ||
| Q3 25 | $7.0M | $40.6M | ||
| Q2 25 | $-4.2M | $6.8M | ||
| Q1 25 | $19.0M | $-11.7M | ||
| Q4 24 | $53.1M | $19.6M | ||
| Q3 24 | $20.0M | $60.0M | ||
| Q2 24 | $21.9M | $3.0M | ||
| Q1 24 | $-12.1M | $-8.4M |
| Q4 25 | 11.8% | -8.7% | ||
| Q3 25 | 3.9% | 18.3% | ||
| Q2 25 | -2.4% | 3.4% | ||
| Q1 25 | 11.3% | -5.7% | ||
| Q4 24 | 29.6% | 9.7% | ||
| Q3 24 | 11.7% | 30.6% | ||
| Q2 24 | 12.8% | 1.7% | ||
| Q1 24 | -7.3% | -4.6% |
| Q4 25 | 3.8% | 10.1% | ||
| Q3 25 | 3.9% | 7.4% | ||
| Q2 25 | 6.3% | 5.5% | ||
| Q1 25 | 4.0% | 5.3% | ||
| Q4 24 | 2.7% | 1.7% | ||
| Q3 24 | 1.8% | 3.8% | ||
| Q2 24 | 3.4% | 4.0% | ||
| Q1 24 | 2.5% | 3.2% |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 3.04× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | 3.89× | -0.07× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | 5.35× | 3.58× | ||
| Q2 24 | 15.44× | 2.01× | ||
| Q1 24 | — | -0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
UTI
| UTI | $142.8M | 65% |
| Concorde | $78.0M | 35% |
